Annual EBITDA
-$70.94 M
-$41.56 M-141.51%
31 March 2022
Summary:
Sio Gene Therapies annual earnings before interest, taxes, depreciation & amortization is currently -$70.94 million, with the most recent change of -$41.56 million (-141.51%) on 31 March 2022. During the last 3 years, it has fallen by -$41.56 million (-141.51%).SIOX EBITDA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Quarterly EBITDA
-$4.48 M
-$1.21 M-36.80%
31 December 2022
Summary:
Sio Gene Therapies quarterly earnings before interest, taxes, depreciation & amortization is currently -$4.48 million, with the most recent change of -$1.21 million (-36.80%) on 31 December 2022.SIOX Quarterly EBITDA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
TTM EBITDA
-$28.66 M
+$20.82 M+42.08%
31 December 2022
Summary:
Sio Gene Therapies TTM earnings before interest, taxes, depreciation & amortization is currently -$28.66 million, with the most recent change of +$20.82 million (+42.08%) on 31 December 2022.SIOX TTM EBITDA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
SIOX EBITDA Performance
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | - | - | - |
| 3 y3 years | -141.5% | +82.3% | +53.2% |
| 5 y5 years | +40.4% | +63.0% | +49.4% |
SIOX EBITDA High & Low
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3 years | ||||||
| 5 y | 5 years | ||||||
| alltime | all time | +141.5% | +52.0% | +15.2% |
Sio Gene Therapies EBITDA History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Dec 2022 | - | -$4.48 M(+36.8%) | -$28.66 M(-42.1%) |
| Sept 2022 | - | -$3.28 M(-60.3%) | -$49.48 M(-26.6%) |
| June 2022 | - | -$8.26 M(-34.6%) | -$67.39 M(-5.0%) |
| Mar 2022 | -$70.94 M(+141.5%) | -$12.64 M(-50.1%) | -$70.94 M(+15.8%) |
| Dec 2021 | - | -$25.31 M(+19.5%) | -$61.25 M(+33.1%) |
| Sept 2021 | - | -$21.18 M(+79.4%) | -$46.01 M(+34.0%) |
| June 2021 | - | -$11.81 M(+300.4%) | -$34.33 M(+16.9%) |
| Mar 2021 | -$29.37 M(-54.6%) | -$2.95 M(-70.7%) | -$29.37 M(-29.5%) |
| Dec 2020 | - | -$10.07 M(+5.9%) | -$41.63 M(-4.7%) |
| Sept 2020 | - | -$9.51 M(+38.8%) | -$43.70 M(-4.8%) |
| June 2020 | - | -$6.85 M(-55.0%) | -$45.90 M(-29.1%) |
| Mar 2020 | -$64.72 M(-45.6%) | -$15.21 M(+25.4%) | -$64.72 M(+14.4%) |
| Dec 2019 | - | -$12.13 M(+3.6%) | -$56.60 M(-25.8%) |
| Sept 2019 | - | -$11.71 M(-54.4%) | -$76.33 M(-20.3%) |
| June 2019 | - | -$25.67 M(+262.1%) | -$95.81 M(-19.5%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Mar 2019 | -$118.95 M(-43.4%) | -$7.09 M(-77.8%) | -$118.95 M(-11.5%) |
| Dec 2018 | - | -$31.86 M(+2.1%) | -$134.40 M(-14.6%) |
| Sept 2018 | - | -$31.20 M(-36.1%) | -$157.41 M(-19.0%) |
| June 2018 | - | -$48.81 M(+116.5%) | -$194.29 M(-7.5%) |
| Mar 2018 | -$210.02 M(+16.3%) | -$22.54 M(-58.9%) | -$210.02 M(-12.8%) |
| Dec 2017 | - | -$54.87 M(-19.4%) | -$240.74 M(+3.0%) |
| Sept 2017 | - | -$68.08 M(+5.5%) | -$233.83 M(+12.8%) |
| June 2017 | - | -$64.54 M(+21.2%) | -$207.26 M(+14.8%) |
| Mar 2017 | -$180.62 M(+35.7%) | -$53.25 M(+11.0%) | -$180.62 M(+14.4%) |
| Dec 2016 | - | -$47.96 M(+15.5%) | -$157.95 M(-8.5%) |
| Sept 2016 | - | -$41.51 M(+9.5%) | -$172.54 M(+18.1%) |
| June 2016 | - | -$37.90 M(+23.9%) | -$146.16 M(+9.8%) |
| Mar 2016 | -$133.15 M | -$30.58 M(-51.1%) | -$133.14 M(+29.8%) |
| Dec 2015 | - | -$62.55 M(+313.5%) | -$102.56 M(+156.4%) |
| Sept 2015 | - | -$15.13 M(-39.2%) | -$40.01 M(+60.8%) |
| June 2015 | - | -$24.88 M | -$24.88 M |
FAQ
- What is Sio Gene Therapies annual earnings before interest, taxes, depreciation & amortization?
- What is the all time high annual EBITDA for Sio Gene Therapies?
- What is Sio Gene Therapies quarterly earnings before interest, taxes, depreciation & amortization?
- What is the all time high quarterly EBITDA for Sio Gene Therapies?
- What is Sio Gene Therapies TTM earnings before interest, taxes, depreciation & amortization?
- What is the all time high TTM EBITDA for Sio Gene Therapies?
What is Sio Gene Therapies annual earnings before interest, taxes, depreciation & amortization?
The current annual EBITDA of SIOX is -$70.94 M
What is the all time high annual EBITDA for Sio Gene Therapies?
Sio Gene Therapies all-time high annual earnings before interest, taxes, depreciation & amortization is -$29.37 M
What is Sio Gene Therapies quarterly earnings before interest, taxes, depreciation & amortization?
The current quarterly EBITDA of SIOX is -$4.48 M
What is the all time high quarterly EBITDA for Sio Gene Therapies?
Sio Gene Therapies all-time high quarterly earnings before interest, taxes, depreciation & amortization is -$2.95 M
What is Sio Gene Therapies TTM earnings before interest, taxes, depreciation & amortization?
The current TTM EBITDA of SIOX is -$28.66 M
What is the all time high TTM EBITDA for Sio Gene Therapies?
Sio Gene Therapies all-time high TTM earnings before interest, taxes, depreciation & amortization is -$24.88 M